Ogasawara Masahiro, Miyashita Mamiko, Yamagishi Yuka, Ota Shuichi
Department of Internal Medicine, Sapporo Hokuyu Hospital, Sapporo, Japan.
Institute for Artificial Organ, Transplantation and Cell Therapy, Sapporo Hokuyu Hospital, Sapporo, Japan.
Ther Apher Dial. 2019 Jun;23(3):279-288. doi: 10.1111/1744-9987.12831. Epub 2019 Jun 6.
The prognosis of metastatic or relapsed head and neck squamous cell carcinoma (HNSCC) remains poor despite the introduction of immune checkpoint blockade agents. We aimed to investigate the safety and the feasibility of a vaccination with Wilms' tumor 1 peptide-loaded dendritic cells (DCs) and OK-432 adjuvant combined with conventional chemotherapy. Eleven eligible patients with metastatic or relapsed HNSCC were enrolled. No severe adverse events related to a vaccination were observed. Five patients had durable stable disease and six other patients had disease progression after DC vaccination. Median progression-free survival and overall survival was 6.4 months and 12.1 months, respectively. DC vaccination augmented Wilms' tumor 1-specific immunity which might be related to clinical outcome. These results indicate that DC-based immunotherapy combined with a conventional chemotherapy is safe and feasible for patients in advanced stage of HNSCC.
尽管引入了免疫检查点阻断剂，但转移性或复发性头颈部鳞状细胞癌（HNSCC）的预后仍然很差。我们旨在研究接种负载肾母细胞瘤1肽的树突状细胞（DCs）和OK-432佐剂并联合传统化疗的安全性和可行性。招募了11例符合条件的转移性或复发性HNSCC患者。未观察到与接种相关的严重不良事件。5例患者病情持续稳定，另外6例患者在DC接种后病情进展。无进展生存期和总生存期的中位数分别为6.4个月和12.1个月。DC接种增强了肾母细胞瘤1特异性免疫，这可能与临床结果相关。这些结果表明，基于DC的免疫疗法联合传统化疗对晚期HNSCC患者是安全可行的。
